AR061500A1 - Un agente antidiabetico para el control de la hiperglucemia diabetica y de las complicaciones relacionadas con la diabetes - Google Patents

Un agente antidiabetico para el control de la hiperglucemia diabetica y de las complicaciones relacionadas con la diabetes

Info

Publication number
AR061500A1
AR061500A1 ARP070102661A ARP070102661A AR061500A1 AR 061500 A1 AR061500 A1 AR 061500A1 AR P070102661 A ARP070102661 A AR P070102661A AR P070102661 A ARP070102661 A AR P070102661A AR 061500 A1 AR061500 A1 AR 061500A1
Authority
AR
Argentina
Prior art keywords
diabetes
diabetic
hyperglucemia
compound
control
Prior art date
Application number
ARP070102661A
Other languages
English (en)
Original Assignee
Indigene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indigene Pharmaceuticals Inc filed Critical Indigene Pharmaceuticals Inc
Publication of AR061500A1 publication Critical patent/AR061500A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe un compuesto de la formula 1 que es la sal de metformina del compuesto biologico endogeno de origen natural, ácido (R)-(+) alfa lipoico, composiciones farmacéuticas que contienen el compuesto de la formula 1 y métodos para el tratamiento de diabetes o complicaciones diabéticas con el compuesto de la formula 1. También se reivindica composicion farmacéutica, kit, método para tratar diabetes y proceso para obtener.
ARP070102661A 2006-06-16 2007-06-15 Un agente antidiabetico para el control de la hiperglucemia diabetica y de las complicaciones relacionadas con la diabetes AR061500A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81425006P 2006-06-16 2006-06-16

Publications (1)

Publication Number Publication Date
AR061500A1 true AR061500A1 (es) 2008-09-03

Family

ID=38669506

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102661A AR061500A1 (es) 2006-06-16 2007-06-15 Un agente antidiabetico para el control de la hiperglucemia diabetica y de las complicaciones relacionadas con la diabetes

Country Status (10)

Country Link
US (1) US7973073B2 (es)
EP (1) EP2046773A1 (es)
JP (1) JP2009541220A (es)
CN (1) CN101522658A (es)
AR (1) AR061500A1 (es)
CA (1) CA2691775A1 (es)
CL (1) CL2007001759A1 (es)
IL (1) IL195959A0 (es)
TW (1) TW200816986A (es)
WO (1) WO2007149313A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935332B2 (en) * 2000-08-16 2011-05-03 Encore Health, Llc Presbyopia treatment by lens alteration
US8697109B2 (en) 2000-08-16 2014-04-15 Encore Health, Llc Caged mercaptan and seleno-mercaptan compounds and methods of using them
US7914815B2 (en) * 2000-08-16 2011-03-29 Encore Health, Llc Method for delivery of pharmaceuticals for treating or preventing presbyopia
US20050112113A1 (en) * 2000-08-16 2005-05-26 Till Jonathan S. Presbyopia treatment by lens alteration
US8647612B2 (en) * 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
WO2008067403A2 (en) * 2006-11-28 2008-06-05 Encore Health Llc Presbyopia treatment by lens alteration
US8102027B2 (en) * 2007-08-21 2012-01-24 Broadcom Corporation IC package sacrificial structures for crack propagation confinement
US20110213021A1 (en) * 2008-03-04 2011-09-01 Indigene Pharmaceuticals, Inc. Compositions and methods for treating nos-associated diseases
WO2009111635A2 (en) 2008-03-05 2009-09-11 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
US9044439B2 (en) 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
WO2009144527A1 (en) * 2008-06-26 2009-12-03 Laboratorios Silanes, S.A. De C.V. A new metformin glycinate salt for blood glucose control
US20100099751A1 (en) * 2008-10-21 2010-04-22 Al-Mulla Fahd Method of treating diabetes-related vascular complications
US8222432B2 (en) * 2008-10-24 2012-07-17 Biolink Life Sciences, Inc. Stable, water-insoluble R-(+)-α-lipoic acid salt useful for the treatment of diabetes mellitus and its co-morbidities
PL2821405T3 (pl) 2009-06-15 2017-08-31 Encore Health, Llc Estry cholinowe do leczenia prezbiopii i zaćmy
WO2010147957A2 (en) 2009-06-15 2010-12-23 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
US8815562B2 (en) 2010-04-15 2014-08-26 The Regenys of the University of Michigan Biosynthetic pathway for heterologous expression of a nonribosomal peptide synthetase drug and analogs
IT1399923B1 (it) * 2010-05-11 2013-05-09 Cbb Net S A Procedimento di preparazione di sali dell'acido (r) alfa-lipoico loro formulazione ed uso nelle composizioni farmaceutiche in forma di compresse che li contengono
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
US8440723B2 (en) * 2011-05-11 2013-05-14 Banavara L. Mylari Metformin salts of salicylic acid and its congeners
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US8853259B2 (en) * 2013-02-07 2014-10-07 Banavara L. Mylari Metformin derivatives for treating diabetes and diabetes complications
WO2015022613A1 (en) * 2013-08-11 2015-02-19 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
US20150073057A1 (en) * 2013-09-06 2015-03-12 Biokier, Inc. Composition and method for treatment of diabetes
CN112641720A (zh) 2014-03-03 2021-04-13 诺华股份有限公司 硫辛酸胆碱酯组合物及使用方法
WO2015171516A1 (en) 2014-05-05 2015-11-12 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
KR20170023061A (ko) 2014-06-18 2017-03-02 테티스 파마수티컬스 엘엘씨 활성제의 미네랄 아미노산 복합체
CA3026264A1 (en) 2016-06-03 2017-12-07 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
JP7038437B2 (ja) * 2017-11-17 2022-03-18 セリックス バイオ プライヴェート リミテッド 眼障害及び皮膚疾患の処置のための化合物、組成物、及び方法
WO2019097318A1 (en) * 2017-11-17 2019-05-23 Cellix Bio Private Limited Compositions and methods for the treatment of eye disorders
CN110037998A (zh) * 2018-01-16 2019-07-23 镇学初 二甲双胍盐在治疗脑梗死中的用途
CN110294738A (zh) * 2019-07-22 2019-10-01 通化师范学院 硫辛酸衍生物及其制备方法和用途
CN113105367B (zh) * 2021-03-30 2022-08-02 广州大学 一类二甲双胍盐及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050085498A1 (en) 1998-05-28 2005-04-21 Byrd Edward A. Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
US6197340B1 (en) * 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
FR2796551B1 (fr) * 1999-07-23 2003-07-25 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
US6693094B2 (en) * 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
WO2003068209A1 (en) * 2002-02-14 2003-08-21 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids

Also Published As

Publication number Publication date
US7973073B2 (en) 2011-07-05
JP2009541220A (ja) 2009-11-26
IL195959A0 (en) 2009-09-22
WO2007149313A1 (en) 2007-12-27
CN101522658A (zh) 2009-09-02
US20070293562A1 (en) 2007-12-20
CA2691775A1 (en) 2007-12-27
CL2007001759A1 (es) 2008-10-24
TW200816986A (en) 2008-04-16
EP2046773A1 (en) 2009-04-15

Similar Documents

Publication Publication Date Title
AR061500A1 (es) Un agente antidiabetico para el control de la hiperglucemia diabetica y de las complicaciones relacionadas con la diabetes
Zhao et al. Hydrogen sulfide (H 2 S) releasing agents: chemistry and biological applications
Greiner et al. Polysulfides link H2S to protein thiol oxidation
Park et al. Synthesis and evaluation of phosphorodithioate-based hydrogen sulfide donors
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
BR122017015106B8 (pt) estrutura de cristal de formula 1b e composição farmacêutica
DE602004015970D1 (de) Verfahren zur überwachung des blutflusses und der metabolischen aufnahme in gewebe mit radioaktiv markierter alkansäure
NI201100081A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa - iv para el tratamiento o prevención de diabetes.
BRPI0517701A8 (pt) métodos de tratamento de diabetes mellitus
BRPI0413276A (pt) derivado de insulina, complexo de zinco do mesmo, composição farmacêutica, e, método para tratar diabete em um paciente
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
BRPI1007622B8 (pt) Composto, composição, método não terapêutico para controlar um nematódeo parasítico e semente revestida
PE20050948A1 (es) Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv
ECSP099330A (es) Compuesto de indol
MA27707A1 (fr) Derives aryles et heteroaryles tri-substitues en position 1,2,3 en tant que modulateurs de metabolisme et prophylaxie et traitement de troubles lies au metabolisme
BR112012007257A2 (pt) Uso de pelo menos um composto, processo de conservação de uma composição, composto e composições cosmética e dermatológica
CO6410287A2 (es) Composición farmacéutica, forma farmacéutica, procedimiento para su preparación, métodos de tratamiento y usos de la misma
CO6190603A2 (es) Acido 7-(2-metilpiridin-3-il carbomoil)-4a-benzil-2-(trifluorometil)-1,2,3,4,4a, 9, 10, 10a-octahidro fenantren-2-il-2-fosfonico como moduladores del receptor glucocorticoide
BRPI0516454A (pt) compostos, processo para a preparação de um composto, composição farmacêutica que o compreende, sua utilização, método para o tratamento e profilaxia de enfermidades, e de diabetes do tipo ii
BRPI0714358B8 (pt) processo para fabricação de um lactil lactato de alquila
BRPI0712889A8 (pt) composto, processo para a preparação de um composto, composto intermediário, e, composição farmacêutica.
PE20191836A1 (es) Compuesto de insulina acilada
PE20191205A1 (es) Composiciones farmaceuticas que contienen insulina
BRPI0506493A (pt) combinações terapêuticas
BRPI0615614A2 (pt) compostos orgánicos

Legal Events

Date Code Title Description
FB Suspension of granting procedure